Explore

TrendlineTrendline
Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront
Rapid ReadRapid Read
Orano Med Expands Lead-212 Production with New U.S. Facility for Cancer Therapies

Orano Med Expands Lead-212 Production with New U.S. Facility for Cancer Therapies

Orano Med, a clinical-stage biotechnology company and subsidiary of the Orano group, is expanding its global manufacturing capabilities for lead-212-based targeted alpha therapies (TATs) for cancer treatment. Following the inauguration of its ATLab Valenciennes in France, which is Europe's first industrial-scale pharmaceutical facility dedicated to producing these radioligand therapies, Orano Med is also commissioning a similar production site in Indianapolis, in the U.S. This U.S. facility is designed to serve the North American market, mirroring the European site's goal of large-scale production to meet patient needs. The company's TATs utilize lead-212 (212Pb), an alpha-emitting radioisotope, as a potent therapeutic payload against cancer cells. Orano Med's strategy involves developing several 212Pb-based radioligand therapies combined with various targeting agents, with four drug candidates currently in clinical development and a broad preclinical pipeline. The logistical demands for these treatments a...
ReutersReuters
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US investment plan, a move expected to expand its workforce in the state by more than 50% in the coming years.
Rapid ReadRapid Read
Blood-Based Biomarkers Revolutionize Alzheimer's Disease Detection and Therapeutic Development

Blood-Based Biomarkers Revolutionize Alzheimer's Disease Detection and Therapeutic Development

Blood-based biomarkers are significantly advancing the detection, monitoring, and therapeutic development for Alzheimer's disease (AD). Frontage Laboratories offers a comprehensive suite of validated neuro biomarker assays to support AD research and drug development. These assays are compatible with advanced platforms such as Quanterix Simoa HD-X, Fujirebio Lumipulse G1200, and Alamar Biosciences, Inc. ARGO HT NULISA, with validated methods for plasma, serum, and cerebrospinal fluid (CSF). Established reference biomarkers for AD pathology, including Amyloid PET and CSF p-tau181/Aβ42, demonstrate high sensitivity and specificity, ranging from 85% to 95%. Additionally, peripherin is emerging as a promising diagnostic and prognostic biomarker for neurodegenerative diseases. This development is crucial given that AD is a complex and progressive neurodegenerative disorder affecting over 55 million people globally, making early and accurate diagnosis critical for effective intervention and management.
Rapid ReadRapid Read
AI Discovers Novel Alzheimer's Drug Candidate Targeting Galectin-3

AI Discovers Novel Alzheimer's Drug Candidate Targeting Galectin-3

A deep-learning platform named Llama-Gram has identified a new drug candidate, FJMU1887, for Alzheimer's disease. This AI-driven discovery process involved screening approximately 2.58 million protein-ligand interactions, incorporating protein structural representations from ESMFold, graph-based representations of chemical compounds, and deep-learning predictions of protein-ligand interactions. The system prioritized candidates based on binding-probability scoring and uncertainty estimation, leading to the selection of FJMU1887. Subsequent laboratory validation confirmed that FJMU1887 directly binds to Galectin-3 (Gal-3) and disrupts its interaction with TREM2, a receptor involved in microglial regulation. In BV-2 microglial cells, FJMU1887 reduced inflammatory responses, including the inhibition of TNF-α, without significant cytotoxicity. The compound also demonstrated the ability to cross the blood-brain barrier, a critical challenge for Alzheimer's drugs, and was detected in the plasma and brain tissue ...
TrendlineTrendline
Novartis Secures $7.8 Billion Licensing Deal with China's Abogen Biosciences for RNA Platform

Novartis Secures $7.8 Billion Licensing Deal with China's Abogen Biosciences for RNA Platform

Novartis Secures $7.8 Billion Licensing Deal with China's Abogen Biosciences for RNA Platform
Rapid ReadRapid Read
DHHS Releases 2026 Unified Agenda, Proposing Five Clinical Research Rule Changes

DHHS Releases 2026 Unified Agenda, Proposing Five Clinical Research Rule Changes

The Department of Health and Human Services (DHHS) has released its 2026 Unified Agenda, outlining five proposed regulatory shifts in clinical research. These changes represent the most concentrated set of proposed modifications to clinical research rules in years. Among the key proposals, the Office for Human Research Protections (OHRP) is considering revisions to 45 CFR 46 (RIN 0937-AA16). These revisions aim to introduce exemptions for low-risk research, provide flexibility for de minimis protocol changes, and reduce the burden on learning health systems. The overarching goal is to concentrate oversight on higher-risk activities. Additionally, the Food and Drug Administration (FDA) is targeting July 2026 for an expedited Phase 1 IND reform (RIN 0910-AJ30), which could revise sponsor responsibilities, risk-based exemptions, and Institutional Review Board (IRB) requirements in early development, with the explicit goal of reducing disproportionate burden. The FDA also lists a single IRB rule for cooperativ...
Rapid ReadRapid Read
FDA Launches Expedited IND Pilot Program and Updates Non-Animal Testing Regulations

FDA Launches Expedited IND Pilot Program and Updates Non-Animal Testing Regulations

The U.S. Food and Drug Administration (FDA) has initiated an Expedited Investigational New Drug (IND) Pilot program, now accepting applications. This program aims to accelerate the drug development process by pairing drug sponsors with Qualified Research Institutions (QRIs) to support IND application preparation. The pilot allows for a rolling review of individual IND components during the pre-IND phase, rather than requiring a complete package upfront, with the goal of reducing clinical holds and shortening the drug-to-first-dose timeline. Applications for this pilot are due by October 30, and the FDA anticipates selecting 8–10 sponsor–QRI pairs for the initial cohort. Concurrently, the FDA has issued a direct final rule replacing 'animal tests' with 'nonclinical tests' in its drug and biologics regulations, explicitly allowing non-animal methods like human cell cultures, organs-on-chips, and computer models for pre-human safety assessment. This change does not eliminate animal studies but clarifies that ...
Rapid ReadRapid Read
FDA Leaders Prioritize Longevity Research, Discuss Approval Pathways for Aging Therapies at ARDD Conference

FDA Leaders Prioritize Longevity Research, Discuss Approval Pathways for Aging Therapies at ARDD Conference

Senior officials from the U.S. Food and Drug Administration (FDA) announced plans to include aging and longevity in the agency's forthcoming update to its Focus Areas of Regulatory Science (FARS). This announcement was made at the Aging Research and Drug Discovery Meeting (ARDD) in Boston. Steven Kozlowski, the FDA's Chief Scientist, indicated that aging and longevity would be a key topic in the 2027 fiscal year FARS update. The panel, which included Jeffrey Siegel, Director of the Office of Drug Evaluation Sciences, and Justin Penzenstadler, Acting Associate Director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology, also discussed potential pathways for the approval of longevity therapies. Two main approaches were outlined: demonstrating that a treatment benefits multiple age-related conditions, or showing that it slows the deterioration of intrinsic capacity across various physical and mental functions. Penzenstadler encouraged sponsors to submit actual protocols and supporting evid...
TrendlineTrendline
Novartis Partners with Abogen Biosciences in $575M+ mRNA Therapeutics Collaboration

Novartis Partners with Abogen Biosciences in $575M+ mRNA Therapeutics Collaboration

Novartis Partners with Abogen Biosciences in $575M+ mRNA Therapeutics Collaboration
TrendlineTrendline
Summit Therapeutics Collaborates with AstraZeneca and Daiichi Sankyo to Evaluate Novel Cancer Combination Therapy

Summit Therapeutics Collaborates with AstraZeneca and Daiichi Sankyo to Evaluate Novel Cancer Combination Therapy

Summit Therapeutics Collaborates with AstraZeneca and Daiichi Sankyo to Evaluate Novel Cancer Combination Therapy
TrendlineTrendline
Sanofi Seeks Head of Platform Partnerships for Vaccine R in U.S. Locations

Sanofi Seeks Head of Platform Partnerships for Vaccine R in U.S. Locations

Sanofi Seeks Head of Platform Partnerships for Vaccine R in U.S. Locations